Tissue engineering in periodontal regeneration: A brief review

Sarita Dabra¹, Kamalpreet Chhina², Nitin Soni³, Rakhi Bhatnagar²

¹Department of Dentistry, M.D.M., Hospital, Dr. S.N. Medical College, Jodhpur, Rajasthan, ²Department of Periodontology and Oral Implantology, B.R.S. Dental College, ³Swami Devi Dyal Hospital and Dental College, Barwala, Panchkula, Haryana, India

ABSTRACT

Periodontal disease is a major public health issue and the development of effective therapies to treat the disease and regenerate periodontal tissue is an important goal of today's medicine. Regeneration of periodontal tissue is perhaps one of the most complex processes to occur in the body. Langer and colleagues proposed tissue engineering as a possible technique for regenerating the lost periodontal tissues. Tissue engineering is a multidisciplinary field, which involves the application of the principles and methods of engineering and life sciences to help in the development of biological substitutes to restore, maintain or improve the function of damaged tissues and organs. A Google/Medline search was conducted and relevant literature evaluating the potential role of the tissue engineering in periodontal regeneration, which included histological studies and controlled clinical trials, was reviewed. A comprehensive search was designed. The articles were independently screened for eligibility. Articles with authentic controls and proper randomization and pertaining specifically to their role in periodontal regeneration were included. The available literature was analyzed and compiled. The analysis indicates tissue engineering to be a promising, as well as an effective novel approach to reconstruct and engineer the periodontal apparatus. Here, we represent several articles, as well as recent texts that make up a special and an in-depth review on the subject. The purpose behind writing this brief review has been to integrate the evidence of research related to tissue engineering so as to implement them in our daily practice.

Key Words: Growth factors, periodontal regeneration, tissue engineering

INTRODUCTION

The ultimate goal of periodontal therapy remains the predictable three-dimensional repair of an intact and functional periodontal attachment that replicates its pre-disease structure. While periodontal treatment, aimed at removing the bacterial cause of the disease is generally very successful. However, the ability predictably to regenerate the damaged tissues still remains a major unmet objective for conventional treatment strategies. Langer in 1993 proposed tissue engineering as a possible technique for regenerating lost periodontal tissues[1]. This field builds on the interface between materials science and biocompatibility, and integrates cells, natural or synthetic scaffolds, and specific signals to create new tissues. Tissue engineering is viewed as synonymous to “regenerative dentistry” because the goal of tissue engineering is to restore tissue function through the delivery of stem cells, bioactive molecules, or synthetic tissue constructs engineered in the laboratory.[2]

The tissue engineering approach to bone and periodontal regeneration combines three key elements to enhance regeneration.

1. Progenitor cells
2. Scaffold or supporting matrix
3. Signaling molecules
**CELL SOURCE FOR PROGENITOR CELLS**

Over the last decade, the regenerative capacity of postnatal progenitor cells has increasingly emerged making these cells an attractive candidate for use in tissue-engineering applications. In particular, cell-based periodontal regeneration has been performed using various approaches and principles, and several excellent reviews have been published recently.[3-5]

**Periodontal ligament-derived cells**

Because periodontal ligament-derived cells have multipotential characteristics, the cells are regarded as useful sources for the regeneration of periodontal tissues containing bone, cementum and periodontal ligament. Nakahara et al. implanted autologous dog periodontal ligament cells that were seeded onto a collagen sponge scaffold into a periodontal fenestration defect model in dogs, and showed regeneration of alveolar bone and cementum in uniform layers on the root surface.[5]

**Periodontal ligament-derived mesenchymal stromal cells**

Seo et al. isolated a population of multipotent stem cells in human periodontal ligament and indicated that periodontal ligament-derived mesenchymal stromal cells exhibited some characteristics similar to those of mesenchymal stromal cells, such as multipotency, clonogenic ability, high proliferation and the expression of the putative stem cell marker STRO-1, as well as the perivascular cell marker CD146.[6]

**Periosteal cells**

The cultured periosteum has the capacity to differentiate into an osteoblastic lineage and expresses periodontal tissue related genes. Yamamiya et al. showed cultured periosteum combined with platelet-rich plasma and hydroxyapatite induced clinical improvements in human infrabony defects.[7]

**Gingival epithelium and fibroblast**

Gingival epithelial sheets derived from human gingival tissues were developed and applied clinically as a treatment for chronic desquamative gingivitis.[8] Transplantation of gingival epithelial sheets induced a reduction in inflammation and the gain of a healthy epithelial junction and connective tissue. Mohammadi et al. applied autologous gingival fibroblasts for patients with insufficient attached gingiva and showed the increase in width of keratinized tissue.[9]

**Bone marrow-derived mesenchymal stem cells**

Using bone marrow aspirates from over 350 human donors, Pittenger and colleagues (1999) showed lineage specific differentiation of MSCs into fat, cartilage, and bone under appropriate in vitro culture conditions. Not only did the human bone marrow derived MSCs demonstrate ability to extensively proliferate, but these cells also were capable of guided differentiation into multiple cell types, establishing a provocative cell source for potential tissue engineering.[3] Kawaguchi et al. demonstrated that autotransplantation of bone marrow derived mesenchymal stem cells induced periodontal regeneration in experimental class III furcation defects in dogs.[10]

**SCAFFOLD OR SUPPORTING MATRICES**

The major roles for supporting matrices are listed below.[11]

1. It serves as a framework, which maintains the shape of the defect. It provides physical support for the healing area so that there is no collapse of the surrounding tissue into the wound site.
2. It serves as a 3D substratum for cellular adhesion, migration, proliferation and production of extracellular matrix.
3. It serves as a barrier to restrict cellular migration in a selective manner.
4. It potentially serves as a delivery vehicle for growth factors.

**BIOMATERIALS USED AS SCAFFOLDS**

**Ceramics**

Natural and synthetic HA (hydroxyapatite) and beta tricalcium phosphate (TCP) are ceramics used in bone tissue engineering. They are biocompatible, osteoconductive and being protein free, they stimulate no immunological reaction.

HA (hydroxyapatite) was one of the first biomaterial to be used as a scaffold. It may be derived from bovine bone or coralline or made of a pure synthetic material. TCP is a naturally occurring material comprising of calcium and phosphorous and is used as a ceramic bone substitute.[12]

**Polymers**

These include synthetic polyesters, such as polyglycolic acid, polylactic acid and polycaprolactone and natural polymers like collagen fibrin, albumin, hyaluronic
acid, cellulose, chitosan, polyhydroxyalkanoates, alginate, agarose and polyamino acids.

**Synthetic polyesters**
PGA (polyglycolic acid) is a polymer of glycolic acid. It was the first polymeric scaffold used in tissue engineering. It is insoluble in water. It is also used as suture material, and as implants for bone fracture fixation.

PLA (polylactic acid) is the polymer of lactic acid. PLA is more hydrophobic than PGA and more resistant to hydrolysis. Copolymers of PGA have been used for many types of biomaterials, including sutures (vicryl).

PLGA (polylactic-co-glycolic acid) is a copolymer of PGA and PLA. Due to its biocompatibility, controlled structural and mechanical properties, tailored degradation rates, and its potential as growth factor delivery vehicles, it has been considered as the prime candidate for use in regenerative medicine and dentistry.

**NATURAL POLYMERS**

**Chitosan**
It is a biodegradable natural carbohydrate biopolymer that has been shown to improve wound healing and improve bone formation. It is non-toxic and non-immunogenic, and have such structural characteristics that makes it possible to be used as a bone substitute and as a scaffold for cell attachment.

**Collagen**

**Collagen foam**
These are fabricated by freeze-drying a solution of collagen and placed in a mold of desired configuration. After physical or chemical cross-linking of sufficient intensity and duration, foam scaffolds become resistant to contraction by tissue cells and exhibit decreased or increased resistance to breakdown by collagenase, depending on the cross-linking regimen.\(^{[13]}\)

**Collagen fiber**
Fibers with diameters of 300-nm and above have been made on a commercial scale. They can be formed into wools by tangling in a scanning electron micrograph of the wool, into which cells are easily seeded. When cross-linked by methods that do not alter the native 67-nm cross-bandings, the fibers are considerably more resistant to collagenase than are foam or gel scaffolds.

**Collagen membrane scaffolds**
Collagen membranes can be prepared by allowing collagen in solution to dry on a surface to which it will not bind, like Teflon or polyethylene. To promote formation of fibrils the solution is neutralized and warmed to 37ºC, allowing the collagen to polymerize and form the fibrils. Before it begins to gel, the solution is spread on a suitable surface and allowed to dry. Membranes may be cross-linked by a variety of methods to improve their wet strength. For example, aldehydic cross-linking will prevent cell attachment, and UV cross-linking will reduce resistance to collagenase.\(^{[14]}\)

**SIGNALLING MOLECULES IN TISSUE ENGINEERING**

In order to enhance the *in vivo* efficacy, incorporation of various bioactive molecules into scaffolding materials have been brought into practice. This incorporation facilitates sustained release of bioactive molecules (growth factors) for longer periods of time. Several bioactive molecules have demonstrated strong effects in promoting periodontal wound repair in preclinical and clinical studies.

**PLATELET DERIVED GROWTH FACTOR**
Kohler and Lipton (1974) and Ross *et al*. (1974) discovered that the material released from platelets is the principal source of mitogenic activity present in serum, and is responsible for the growth of many cells in culture that are serum dependent. This activity was later localized to the alpha granules within platelets by Witte *et al*. 1978, Kaplan *et al*. 1979 and called platelet derived growth factor (Ross and Vogel, 1978). PDGF is a dimeric molecule comprising of two peptide chains termed as A and B chains. It is considered to be a potent mediator of periodontal tissue regeneration. It is chemotactic and mitogenic for periodontal ligament cells. It stimulates gingival fibroblast hyaluronate synthesis, a pre requisite for the formation of large aggregate of proteoglycans that provide the lattice for extracellular matrix. Furthermore, alkaline phosphatase activity and osteocalcin are down regulated by PDGF, thereby enhancing bone and cementum formation. Samuel E. Lynch (1991)\(^{[15]}\) demonstrated that short term application of the combination of PDGF-B and IGF-I can significantly enhance the formation
of periodontal attachment apparatus during early phases of wound healing following surgery. Moon-II Cho (1995)\textsuperscript{[16]} conducted an animal study on beagle dogs and introduced the “PDGF modulated guided tissue regeneration therapy”. He concluded that PDGF-BB modulated therapy promotes periodontal regeneration more rapidly and effectively as compared to GTR alone. Recombinant human platelet-derived growth factor-BB homodimer is approved for the treatment of periodontal defects and is commercially available as Gem-21 (Osteohealth, Shirley, NY).

**FIBROBLAST GROWTH FACTOR**

Fibroblast growth factor is the member of heparin binding growth factor family. There are 7 forms of fibroblast growth factor. It can be isolated from normal tissues in two forms: Acidic FGF (aFGF) and basic FGF (bFGF). Besides its name its activity exists beyond that of fibroblast and includes a wide variety of cell types such as smooth muscles, endothelial cells, chondrocytes and osteoblasts. Being a mitogen for fibroblasts, osteoblasts, chondrocytes, smooth muscle cells, skeletal myoblast, it has a profound effect on periodontal soft tissue and bone healing. FGF also stimulates angiogenesis, DNA synthesis and cell replication. Terranova (1989)\textsuperscript{[17]} et al. demonstrated that β-FGF stimulated human endothelial and periodontal ligament cell migration and proliferation in concentration as low as 10 mg per dentin block and also combination with an attachment protein called fibronectin further enhances periodontal cell chemotaxis.

**BONE MORPHOGENETIC PROTEINS**

These are 15 different types of proteins identified to date as a part of transforming growth factor-β superfamily. Bone morphogenetic protein-2 is a disulfide-linked homodimer. BMP appears to possess a multitude of effects that promote periodontal healing. It helps undifferentiated pluripotent cells to differentiate into cartilage and bone forming cells.\textsuperscript{[18]} Along with β-FGF, it stimulates angiogenesis. It also stimulates alkaline phosphatase activity, thereby promoting bone formation. Thorarinn J. Sigurdsson (1995)\textsuperscript{[19]} did a study on beagle dog with artificially created 5 mm deep bone defects and concluded that rhBMP-2 treated sites showed higher alveolar bone level when compared with the control sites. Atsuhiro Kinoshita (1997) examined the regeneration of periodontal tissue after the application of rhBMP-2 to horizontal circumferential defects created by experimental periodontitis in adult beagle dogs. The combination of rhBMP-2 on an absorbable collagen sponge carrier is commercially available as Infuse bone graft and is applied for bone augmentation for sinus lifting and implant dentistry.\textsuperscript{[20]}

**INSULIN LIKE GROWTH FACTOR**

This class of growth factors is also referred to as somatomedins. IGF-I is known as somatomedin C and IGF-II has been called multiplication-stimulating activity.

Insulin like growth factor-I is found in substantial levels in platelets and is released during clotting along with the other growth factors. It is a potent chemotactic agent for vascular endothelial cells resulting in increased neovascularization. IGF-1 has strong effect on periodontal ligament fibroblasts mitogenesis and protein synthesis \textit{in vitro}. It promotes osteogenesis and cementogenesis.\textsuperscript{[21]} IGF-II is the most abundant growth factor in the bone and it also promotes parameters of bone formation but is not as potent as IGF1. Matsuda \textit{et al.} (1992)\textsuperscript{[22]} demonstrated the mitogenic effects of IGF-I on periodontal ligament fibroblastic cells and concluded that a synergistic effect results from using a combination of PDGF-AB and IGF-1. Soren Blom \textit{et al.} 1992\textsuperscript{[23]} concluded that IGF-I can stimulate the synthesis of DNA in periodontal ligament fibroblast, likely via binding to high affinity cell surface receptors.

**TRANSFORMING GROWTH FACTOR-β**

TGF-β was originally identified because it can induce non-transformed cells to grow in soft agar. It is found in highest concentration in bone and platelets. TGF-β is encoded by three different genes TGF-β\textsubscript{1}, TGF-β\textsubscript{2}, and TGF-β\textsubscript{3}. TGF-β is a strong promoter of extracellular matrix production. It selectively stimulates periodontal ligament fibroblast proliferative activity. It stimulates type I collagen, fibronectin and osteocalcin biosynthesis, as well as bone matrix deposition and chemotaxis of osteoblast. On the other hand, TGF-β decreases synthesis of metalloproteinases and plasminogen activator, and also increases the synthesis of tissue inhibitor of metalloproteinases and plasminogen activator inhibitor (PAI), thus resulting in the
decrease of connective tissue destruction. TGF-also appears to inhibit formation of osteoclast like cells. Due to its pleiotropic effects on bone matrix formation and resorption and its relative abundance in bone, it may act as bone coupling factor linking bone resorption to bone formation.[24]

PERIODONTAL LIGAMENT DERIVED GROWTH FACTOR

Nishimura et al. (1995) isolated a novel polypeptide factor from human periodontal cells periodontal ligament derived growth factor called PDL-CTX. This peptide is highly specific autocrine chemotactic agent for human periodontal ligament cells, which is 1000 fold more potent than many known growth factors (IGF, PDGF, TGF). In addition, PDL-CTX has no chemotactic effect on gingival fibroblast or epithelial cells thereby promising its utility for biological therapeutic regime needed for cell specific periodontal regeneration.[24]

RECENT ADVANCEMENTS IN TISSUE ENGINEERING

Gene therapy
The single administration of purified tissue growth factors has not been shown to be clinically effective in supporting the horizontal regeneration of periodontal tissue breakdown because of their short biological half-lives. Once applied, these factors are subject to proteolytic breakdown and receptor-binding problems and are dependent on the stability of the carrier system. Gene therapy may circumvent many of the limitations with protein delivery to soft tissue wounds.[25,26] Gene therapy refers to the treatment of a disease by means of a genetic manipulation. Genetic information is transferred to the target cells, which enables them to synthesize a protein of interest to treat disease. Gene transfer is accomplished through the use of viral [retroviruses, adenoviruses (Ad) and adeno-associated viruses (AAV)] and non-viral vectors (plasmids and DNA polymer complexes.[27] Gene vectors can be introduced directly to the target site (in vivo technique), or selected cell can be harvested, expanded, genetically transduced, and then reimplanted (ex vivo technique).[27] The application of growth factors or soluble forms of cytokine receptors by gene transfer provides a greater sustainability and bioavailability of growth factors within periodontal wounds.[28]

GENE THERAPY FOR PERIODONTAL TISSUE ENGINEERING

Platelet derived growth factor gene delivery
Plasmid and Ad/PDGF gene delivery have been evaluated in preclinical and human trials. The latter approach has been able to exhibit more safety favorable for clinical use, however.[27] An ex vivo investigation by Anusaksathein and colleagues showed that the expression of PDGF genes was prolonged for up to 10 days in gingival wounds. Ad encoding PDGF B transduced gingival fibroblasts and enhanced defect fill by induction of human gingival fibroblasts migration and proliferation. On the other hand, continuous exposure of cementoblasts to PDGF A had an inhibitory effect on cementum mineralization, possible via the upregulation of osteopontin and subsequent enhancement of multinucleated giant cells in cementum-engineered scaffolds. Jin and colleagues demonstrated that direct in vivo gene transfer of PDGF-B stimulated tissue regeneration in large periodontal defects. Descriptive histology and histomorphometry revealed that human PDGF-B gene delivery promotes the regeneration of cementum and alveolar bone, whereas PDGF-1308, a dominant negative mutant of PDGF-A, has minimal effects on periodontal tissue regeneration.[27]

Bone morphogenetic proteins gene delivery
An experimental study in rodents by Lieberman and Colleagues demonstrated gene therapy for bone regeneration, with results revealing that the transduction of bone marrow stromal cells with rh BMP-2 lead to bone formation within an experimental defect comparable to skeletal bone. Another group was similarly able to regenerate skeletal bone by directly administering Ad5/BMP-2 providing further evidence for the ability of in vivo and ex vivo bone engineering. Francheshi and colleagues investigated in vitro and in vivo Ad gene transfer of BMP-7 for bone formation. Ad transduced non osteogenic cells also were found to differentiate into bone-forming cells and produce BMP-7 or BMP-2 in vitro and in vivo.[27] When genes that encoded the BMP antagonist noggin were delivered, inhibition of periodontal tissue formation resulted.[27] A recent study by Dunn and colleagues showed that direct in vivo gene delivery of Ad/BMP-7 in a collagen gel carrier promoted successful regeneration of alveolar bone defects around dental implants.[27]
Gene therapy presents certain advantages when compared with other therapies. Because both cell transplantation and laboratory cell culturing are not needed, gene therapy may be safer and more cost-effective than cell-based therapies.\(^{[30]}\) Moreover, when compared with the existing recombinant single-protein-based therapies, gene therapy may mimic the complex natural process of periodontal tissue formation, because multiple genes, and multiple factors, can be delivered within the bone defect.\(^{[30]}\)

**Ribonucleic acid mediated silencing**

The ribonucleic acid (RNA)-mediated silencing process is defined as RNAi, a discovery for which Fire and Mellow received the 2006 Nobel Prize.\(^{[31]}\) It is based on the principle of RNA interference (RNAi), a novel mechanism of action whereby the expression of certain genes detrimental to the tissue regeneration process is silenced by RNAs. RNAi works through small RNAs of approximately 20 to 30 nucleotides that guide the degradation of complementary or semi complementary molecules of messenger RNAs (posttranscriptional gene silencing) or interfere with the expression of certain genes at the promoter level (transcriptional gene silencing). Artificially, transcribed short hairpin RNAs (shRNAs) can be introduced into the cell by plasmid transfection or viral transduction, or small linear RNAs (siRNA) can be directly transfected into the cells. In the cytoplasm, the shRNAs or siRNA participate in endogenous posttranscriptional gene silencing. The synthetic RNAs are recognized and processed by an endoribonuclease named Dicer and incorporated into the RNA-induced silencing complex. Then, silencing occurs through the AGO2-mediated cleavage of target messenger RNAs. Most RNA-based therapeutics currently under investigation use siRNAs because they are safe and cost-effective. They can be introduced into the cells without the aid of viruses and can be chemically synthesized. The first siRNA-based therapeutic tested in human clinical trials was the VEGF-targeted RNA for the treatment of macular degeneration of the retina. Tumor necrosis factor-\(\alpha\)-targeted siRNA can suppress osteolysis induced by metal particles in a murine calvaria model, opening the way to the application of RNAi in orthopaedic and dental implant therapy. In terms of bone regeneration, Gazzerro and colleagues have demonstrated that downregulation of Gremlin by RNAi in ST-2 stromal and MC3T3 osteoblastic cells increases the BMP-2 stimulatory effect on alkaline phosphatase activity and on Smad 1/5/8 phosphorylation, enhances osteocalcin and Runx-2 expression, and increases Wnt signaling, with the potential to increase bone formation in vivo. Taken together, these studies prove that RNAi, when adequately used, can foster tissue regeneration. The use of RNA-based therapeutics for tissue regeneration is still in its early stages. Nevertheless, RNAi promises to be an effective therapeutic tool and may be successful in periodontal regeneration.\(^{[31]}\)

**Implantation of live cells**

Effective augmentation techniques to treat more challenging esthetic concerns, such as open interproximal spaces and other severe oral soft-tissue deficiencies, though, are not currently available but cell-based therapies may change this. Enumerated below are some of the examples enlightening the use of live cell based therapy in the field of periodontics.

**Treatment of papillary insufficiency by transplantation of autologous cultured and expanded fibroblasts**

Mcguire and Scheyer\(^{[32]}\) assessed the efficacy and safety of using autologous fibroblast injections following a minimally invasive papilla priming procedure to augment open interproximal spaces. Two primary sites were selected and randomized to receive autologous fibroblast injections or placebo injections. The primary efficacy parameter was the percentage change in papillary height of the primary treatment areas from baseline to the 4-month visit, as measured by a periodontal probe from the base of the contact area to the tip of the interproximal papilla. The analysis of the investigator and subject visual analog scale (VAS) assessments indicated the test treatment to be superior to the placebo treatment. Preliminary results indicate that this novel tissue-engineering technique may hold promise in resolving the challenging open interproximal space. Further research is under way to evaluate this as a predictable therapy.

**Treatment of deep periodontal pockets with autologous fibroblasts or placebo**

Bowsma and D Souza (2005)\(^{[33]}\) used autologous fibroblasts expanded in vitro for soft tissue contouring. Each subject provided a 3mm oral biopsy from which fibroblasts were isolated and expanded. A series of 3 injections of either autologous fibroblasts or placebo product was made into each study site. Deep
periodontal pockets treated with autologous fibroblasts had a statistically significant reduction in pocket depth compared to those treated with placebo.

**Use of tissue engineered human fibroblast derived dermal substitute to increase the amount of keratinized tissue**

HF-DDS is a tissue engineered human dermal replacement graft manufactured through a three dimensional cultivation of human diploid fibroblast cells on a polymer scaffold. Human fibroblast cell strains are obtained from newborn foreskins and are cultured by standard methods. The fibroblasts remain metabolically active after implantation and deliver growth factors key to neovascularization, cell migration and differentiation. Unlike keratinocytes which carry surface human leukocyte antigens that may cause allograft rejection phenomenon, implantation of allogenic human fibroblasts does not stimulate an immune response. The tissue engineered HF-DDS graft is safe and capable of generating keratinized tissue without the morbidity and the clinical difficulties associated with donor site surgery (Mc Guire and Todd Scheyer).

**Bilayered cell therapy: A tissue engineered skin substitute as an alternative to tissue from palate**

Bilayered cell therapy is a living bilayered tissue engineered skin substitute constructed of type I bovine collagen and viable allogenic human fibroblasts and keratinocytes isolated from human foreskin. BCT is morphologically, biochemically and metabolically similar to human skin. Its cell proliferation rate is similar to that of human skin. Mitotic activity occurs in the basal keratinocytes of the epidermis and in the fibroblasts within the matrix. The keratinocytes produce growth factors and cytokines that act as signals between cells and help to regulate normal wound healing. Bilayered cell therapy exhibits a synergistic interaction between epidermal and dermal layers. It enhances cell and tissue differentiation through cell: Matrix, cell: Cell and cell: Environment interactions. BCT is safe and capable of generating keratinized tissue without the morbidity and potential difficulties associated with donor site surgery (Mc Guire and Todd Scheyer).

**Human cultured gingival epithelial sheet for promoting tissue regeneration and the concept behind**

Momose et al. measured the levels of growth factors released from human cultured gingival epithelial sheets (HCGES) into culture medium. Gingival tissues were obtained from patients of generalized chronic periodontitis during periodontal flap surgery. The levels of vascular endothelial growth factor (VEGF), transforming growth factor-α and β1 (TGF-α and β1), and epidermal growth factor (EGF) released into the culture medium were determined using enzyme linked immunosorbent assay at just confluent T1 and adequate stratification T2 culture stages. The medium without cells was collected as control (T0). Significantly higher levels of VEGF and TGF-α at T1 and T2 as compared to T0 was found, thereby suggesting the potential of HCGES for promoting wound healing and tissue regeneration after grafting. Besides reducing post-operative discomfort by avoiding the necessity for a tissue graft from the donor site, HCGES being autograft materials, are expected to adhere permanently after grafting because of little influence from immunological rejection. In addition, the availability of frozen cultured epithelial sheets allows several clinical applications for the same patient over a certain period of time from only one biopsy.

Implanting live cells is a new dimension of treatment. It is hoped that the live cells will communicate with native cells, optimizing the influx of metabolically active molecules at the appropriate time and in the quantity required by the wound. It will not be long before live cell technologies are available in the dental office. These technologies not only deliver growth factors but also provide a template for cell migration, adhesion, proliferation, and differentiation, thus optimizing the site-specific regenerative response.

**ANALYTICAL EVALUATION**

1. Although the use of growth factors, through tissue engineering seem to be very promising for periodontal regeneration, well-defined discriminating preclinical models followed by well-designed clinical trials are needed to further investigate the true potential of these growth and differentiation factors.

2. Even for the PDGF/IGF-1 combination, the optimum dose and optimum number of doses must still be determined. An alternative to repeated applications would be the incorporation of the growth factors into a controlled release delivery system, which will enable the controlled release of signaling molecules in to the defect for prolonged periods of time. Such a system might be designed to also take advantage of the principles of guided

---

**Dabra, et al.: Tissue engineering in periodontal regeneration**

**Vol 9  /  Issue 6**

**677**
tissue regeneration. Barrier membranes exclude non-desirable cells from the periodontal wound but do not **per se** stimulate desirable cells. The effect of using growth factors underneath barrier membranes deserves further study.

3. The mechanisms, by which PDGF/IGF-1 (and perhaps other growth factors) acts to enhance periodontal regeneration, yet remain to be proven **in vivo**. Tritiated thymidine and proline labeling studies would yield valuable information on the **in vivo** effects of these growth factors on the proliferation, migration, and matrix synthesis of cells from the bone and periodontal ligament.

4. The clinical results, as well as histologically evaluated periodontal regeneration obtained using rh PDGF and rh BMP is much superior, but patient-centered outcomes, including adverse effects, cost effectiveness, and risk benefit have been evaluated in a very limited number of studies.

5. Although our understanding of gene regulation of PDGF and BMP has improved with experimental gene therapy studies, the safety and efficacy of using gene therapy for regeneration is yet to be evaluated.

6. Majority of these studies have been conducted in animals, which include beagle dogs and rodents. While some species are more suited than others, these findings may not always be directly extrapolated to humans.

7. The actual use of cell seeding in a periodontal application has been limited to a fewer number of studies, and some of these studies have a small sample size. Although preliminary periodontal results appear encouraging, extensive characterization would be necessary before this technique could become a clinical reality. Also, these cell based therapies need to be validated with human histology and other well-controlled, randomized clinical trials.

**POTENTIAL CHALLENGES YET TO OVERCOME**

To date, a number of studies have reported that progenitor cells, in conjunction with different physical matrices and growth factors, have the capacity to regenerate periodontal tissues **in vivo**. Notwithstanding these significant advances, there are still numerous biological, technical and clinical hurdles to be overcome:

1. Complete understanding about the molecular and signalling pathways that form the ground for tissue engineering and underlie cell renewal and differentiation is yet to obtain.

2. As cell culture medium often requires xenogenic products (such as fetal bovine serum or mouse feeder layers), cell cultures may not be completely free of pathogens and infectious risks are a concern.

3. Culture conditions are not sufficiently developed to mimic the cell microenvironment **in vivo**. The ideal matrix scaffold should mimic native extracellular matrix, support cell attachment, allow controlled release of bioactive factors, be conducive to tissue in growth and facilitate laboratory handling.\[^{37}\]

4. Clinical challenges in cell based periodontal therapy relate to immune rejection after administration of stem cells into the host. A potential solution to this problem lies in the use of autologous stem cells to overcome immune rejection.\[^{38}\]

5. During the extended period in culture, there is a greater likelihood for genetic or epigenetic changes in stem cells.\[^{39}\] Recently, it was hypothesized that bone-marrow-derived mesenchymal stem cells could be a source of carcinoma-associated fibroblasts (CAF), which has an important role in the growth of epithelial solid tumors (Mishra *et al*., 2009).\[^{40}\] The challenge relating to genomic stability and the risk of tumorigenesis following stem cell transplantation are major safety considerations.

**FUTURE PERSPECTIVE**

Though, a number of unknowns still remain to be answered, with the continued development of improved methods for gene delivery to cells, as well as advances in our knowledge of the molecular basis of periodontal homeostasis, it is reasonable to anticipate that a simple chairside protocol could be developed in the future. This might involve either the direct delivery of the DNA of interest to the periodontal tissue, or the isolation of a small amount of gingival tissue from the patient, transduction/transfection of the DNA at chairside, and reimplantation of the gene-enhanced cells into the tooth or periodontal ligament space, which might dramatically improve patients' quality of life by providing accurate therapies with fewer side effects, shorter treatment times, and
optimal predictability. Further investigation with recombinant growth factors and cell therapy needs to be conducted to support these methods for everyday clinical practice.

REFERENCES

1. Langer R, Vacanti JP. Tissue engineering. Science 1993;260:920-6.
2. Kumar A, Mukhtar-Un-Nisar S, Zia A. Tissue Engineering-The promise of regenerative dentistry. Biol Med 2011;3:108-13.
3. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
4. Nakahara T. A review of new developments in tissue engineering for periodontitis. Dent Clin North Am 2006;50:265-76.
5. Nakahara T, Nakamura T, Kobayashi E, Kuremoto K, Matsuno T, Tabata Y, et al. In situ tissue engineering of periodontal tissues by seeding with periodontal ligament-derived cells. Tissue Eng 2004;10:537-44.
6. Seo BM, Miura M, Gronthos S, Bartold PM, Batouli S, Brahim J, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. J Periodontol 2008;79:811-8.
7. Yamamiya K, Okuda K, Kawase T, Hata K, Wolff LF, Yoshie H. Tissue-engineered cultured periosteum used with platelet-rich plasma and hydroxyapatite in treating human osseous defects. J Periodontol 2007;84:149-55.
8. Okuda K, Momose M, Murata M, Saito Y, Inoie M, Shihohara C, et al. Treatment of chronic desquamative gingivitis using tissue-engineered human cultured gingival epithelial sheets: A case report. Int J Periodontics Restorative Dent 2004;24:119-25.
9. Mohammad M, Shokrogoz MA, Mofid R. Culture of human gingival fibroblasts on a biodegradable scaffold and evaluation of its effect on attached gingiva: A randomized, controlled pilot study. J Periodontol 2007;78:1897-903.
10. Kawaguchi H, Hirachi A, Hasegawa N, Iwata T, Hamaguchi H, Shibahara Y, et al. Enhancement of periodontal tissue regeneration by transplantation of bone marrow mesenchymal stem cells. J Periodontol 2004;75:1281-7.
11. Kao RT, Murakami S, Birne OR. The use of biologic mediators and tissue engineering in dentistry. Periodontol 2000 2009;50:127-53.
12. Olson DP, Abukawa H, Vacanti JP. Three dimensional printed beta-TCP scaffold for bone tissue engineering (abstract). Presented at the American association of oral and maxillofacial surgeons 2004 annual meeting. San Francisco (CA): September 29-Oct 2, 2004.
13. Abukawa H, Papadaki M, Abulikemu M, Leaf J, Vacanti JP, Kaban LB, et al. The engineering of craniofacial tissues in the laboratory: A review of biomaterials for scaffolds and implant coatings. J Periodontol 2006;80:205-16, viii.
14. Nakahara T. A review of new developments in tissue engineering therapy for periodontitis. In; Godoy FG, editor. Tissue engineering Dental Clinics of North America. Vol 50. Philadelphia: Saunders; 2006.
15. Lynch SE, Buser D, Hernandez RA, Weber HP, Stich H, Fox CH, et al. Effects of platelet derived growth factor/insulin like growth factor-1 combination on bone regeneration around titanium implants. Results of a pilot study on beagle dogs. J Periodontol 1991;62:710-6.
16. Cho M, Lin WL, Genco RJ. Platelet-Derived growth factor modulated guided tissue regenerative therapy. J Periodontol 1995;66:522-30.
17. Terranova VP, Odziemiec C, Twened KS, Spadone DP. Repopulation of dentin surfaces by periodontal ligament cells and endothelial cells. Effect of basic fibroblast growth factor. J Periodontol 1989;60:293-301.
18. Wozney JM, Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Relat Res 1998;346:26-37.
19. Sigurdsson TJ, Lee MB, Kubota Kl. Periodontal repair in dogs: Recombinant bone morphogenetic protein 2 significantly enhances periodontal regeneration. J Periodontol 1995;66:131-8.
20. Schliepake H, Aref A, Scharnweber D, Bieberbaum S, Roessler S, Sewing A. Effect of immobilized bone morphogenetic protein 2 coating of titanium implants on perimplant bone formation. Clin Oral Implants Res 2005;16:563-9.
21. Bennett NT, Schultz GS. Growth factors and wound healing: Biochemical properties of growth factors and their receptors. Am J Surg 1993;165:728-37.
22. Matsuda N, Lin WL, Kumar NM, Cho MI, Genco RJ. Mitogenic, chemotactic and synthetic response of rat periodontal ligament fibroblastic cells to polypeptide growth factors in vitro. J Periodontol 1992;63:515-25.
23. Blom S, Holmstrup P, Dabelsteen E. The effect of insulin like growth factor 1 and human growth hormone on periodontal ligament fibroblast morphology, growth pattern, DNA synthesis and receptor binding. J Periodontol 1992;63:960-8.
24. Position Paper. The potential role of growth and differentiation factors in periodontal regeneration. J Periodontol 1996;67:545-53.
25. Abramson ZR, Jin QM, Giannobile WV. Gene therapies for periodontal regenerative medicine. Dent Clin N Am 2006;50:245-63.
26. Giannobile WV. What does the future hold for periodontal tissue engineering? Int J Periodontics Restorative Dent 2002;22:6-7.
27. Ramsier CA, Abramson ZR, Jin Q, Giannobile WV. Gene therapies for periodontal regenerative medicine. Dent Clin N Am 2006;50:245-63.
28. Jin QM, Anusakathai O, Webb SA, Rutherford RB, Giannobile WV. Gene therapy of bone morphogenetic protein for periodontal tissue engineering. J Periodontol 2003;74:202-13.
29. Franceschi RT. Biological approaches to bone regeneration by gene therapy. J Dent Res 2005;84:1093-103.
30. Nevins M, Giannobile WV, McGuire MK, Kao RT, Mellonig JT, Hinrichs JE, et al. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: Results of a large multicenter randomized controlled trial. J Periodontol 2005;76:2205-15.
31. Intini G. Future approaches in periodontal regeneration: Gene therapy, stem cells and RNA interference. Dent Clin N Am 2010;54:141-55.
32. McGuire MK, Scheyer ET. A randomized, double blind, placebo controlled study to determine the safety and efficacy of cultured and expanded autologous fibroblast injections for the treatment of interdental papillary insufficiency associated with papilla
Dabra, et al.: Tissue engineering in periodontal regeneration

33. Bowsma O, D’souza R, Meyerat BS. Treatment of deep periodontal pockets with autologous fibroblasts or placebo. J Dent Res 2005;84:107.

34. McGuire MK, Nunn ME. Evaluation of the safety and efficacy of periodontal applications of a living tissue engineered human fibroblast-derived dermal substitute. Comparison to the gingival autograft: A randomized controlled pilot study. J Periodontol 2005;76:867-80.

35. McGuire MK, Scheyer ET, Nunn ME, Lavin PT. A pilot study to evaluate a tissue engineered bilayered cell therapy as an alternative to tissue from the palate. J Periodontol 2008;79:1847-56.

36. Momose M, Murata M, Kato Y, Okuda K, Yamazaki K, Shinohara C, et al. Vascular endothelial growth factor and Transforming growth factor-α and -β1 are released from human cultured gingival epithelial sheets. J Periodontol 2002;73:748-53.

37. Bartold PM, Xiao Y, Lyngstaadas SP, Paine ML, Snead ML. Principles and applications of cell delivery systems for periodontal regeneration. Periodontol 2000 2006;41:123-35.

38. Choumerianou DM, Dimitriou H, Kalmanti M. Stem cells: Promises versus limitations. Tissue Eng Part B Rev 2008;14:53-60.

39. Bongso A, Fong CY, Gauthaman K. Taking stem cells to the clinic: Major challenges. J Cell Biochem 2008;105:1352-60.

40. Mishra PJ, Mishra PJ, Glod JW, Banerjee D. Mesenchymal stem cells: Flip side of the coin. Cancer Res 2009;69;1255-8.

How to cite this article: Dabra S, Chhina K, Soni N, Bhatnagar R. Tissue engineering in periodontal regeneration: A brief review. Dent Res J 2012;9:671-80.

Source of Support: Nil. Conflict of Interest: None declared.

Author Help: Online submission of the manuscripts

Articles can be submitted online from http://www.journalonweb.com. For online submission, the articles should be prepared in two files (first page file and article file). Images should be submitted separately.

1) First Page File: Prepare the title page, covering letter, acknowledgement etc. using a word processor program. All information related to your identity should be included here. Use text/rtf/doc/pdf files. Do not zip the files.

2) Article File: The main text of the article, beginning with the Abstract to References (including tables) should be in this file. Do not include any information (such as acknowledgement, your names in page headers etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file size to 1 MB. Do not incorporate images in the file. If file size is large, graphs can be submitted separately as images, without their being incorporated in the article file. This will reduce the size of the file.

3) Images: Submit good quality color images. Each image should be less than 4 MB in size. The size of the image can be reduced by decreasing the actual height and width of the images (keep up to about 6 inches and up to about 1800 x 1200 pixels). JPEG is the most suitable file format. The image quality should be good enough to judge the scientific value of the image. For the purpose of printing, always retain a good quality, high resolution image. This high resolution image should be sent to the editorial office at the time of sending a revised article.

4) Legends: Legends for the figures/images should be included at the end of the article file.